Sol Gel Technologies Ltd (NASDAQ:SLGL) Expected to Post Quarterly Sales of $1.93 Million

Brokerages expect Sol Gel Technologies Ltd (NASDAQ:SLGL) to announce $1.93 million in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Sol Gel Technologies’ earnings, with estimates ranging from $1.40 million to $2.70 million. Sol Gel Technologies reported sales of $4.73 million in the same quarter last year, which indicates a negative year over year growth rate of 59.2%. The company is scheduled to announce its next quarterly earnings report on Wednesday, November 11th.

On average, analysts expect that Sol Gel Technologies will report full-year sales of $8.89 million for the current fiscal year, with estimates ranging from $7.40 million to $10.87 million. For the next financial year, analysts anticipate that the firm will post sales of $31.90 million, with estimates ranging from $17.90 million to $46.40 million. Zacks’ sales averages are a mean average based on a survey of research firms that that provide coverage for Sol Gel Technologies.

Sol Gel Technologies (NASDAQ:SLGL) last posted its earnings results on Thursday, August 6th. The company reported ($0.31) EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.01. Sol Gel Technologies had a negative net margin of 210.73% and a negative return on equity of 46.18%.

Several brokerages have recently issued reports on SLGL. Zacks Investment Research cut shares of Sol Gel Technologies from a “hold” rating to a “sell” rating in a research report on Tuesday, July 21st. HC Wainwright restated a “buy” rating and set a $21.00 price objective on shares of Sol Gel Technologies in a report on Tuesday, June 30th. Finally, Raymond James reaffirmed a “buy” rating on shares of Sol Gel Technologies in a research report on Tuesday, September 1st. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $22.05.

Sol Gel Technologies stock traded up $0.25 during mid-day trading on Friday, hitting $7.80. The stock had a trading volume of 17,702 shares, compared to its average volume of 46,075. The company has a current ratio of 9.94, a quick ratio of 9.94 and a debt-to-equity ratio of 0.02. Sol Gel Technologies has a one year low of $5.00 and a one year high of $21.00. The firm’s 50 day moving average is $7.70 and its 200 day moving average is $7.95. The firm has a market capitalization of $159.04 million, a P/E ratio of -5.86 and a beta of 1.44.

Institutional investors have recently modified their holdings of the stock. Canada Pension Plan Investment Board purchased a new stake in shares of Sol Gel Technologies in the 2nd quarter valued at approximately $90,000. Bank of Montreal Can boosted its position in shares of Sol Gel Technologies by 4.2% during the second quarter. Bank of Montreal Can now owns 54,775 shares of the company’s stock worth $441,000 after buying an additional 2,225 shares during the period. Raymond James Financial Services Advisors Inc. grew its stake in shares of Sol Gel Technologies by 20.0% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 52,649 shares of the company’s stock valued at $472,000 after buying an additional 8,764 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. raised its holdings in shares of Sol Gel Technologies by 0.5% in the 2nd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 927,333 shares of the company’s stock valued at $8,303,000 after buying an additional 5,000 shares during the period. Finally, Phoenix Holdings Ltd. lifted its stake in Sol Gel Technologies by 28.1% during the 1st quarter. Phoenix Holdings Ltd. now owns 2,701,847 shares of the company’s stock worth $18,631,000 after acquiring an additional 592,068 shares in the last quarter. Institutional investors own 32.08% of the company’s stock.

About Sol Gel Technologies

Sol-Gel Technologies Ltd., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include TWIN and SIRS-T, which has completed Phase II clinical trials for the treatment of acne vulgaris; and VERED that has completed Phase II clinical trials for the treatment of papulopustular rosacea.

Recommended Story: What is the return on assets formula?

Get a free copy of the Zacks research report on Sol Gel Technologies (SLGL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sol Gel Technologies (NASDAQ:SLGL)

Receive News & Ratings for Sol Gel Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sol Gel Technologies and related companies with MarketBeat.com's FREE daily email newsletter.